PT - JOURNAL ARTICLE AU - Solomon M. Adams AU - Habiba Feroze AU - Tara Nguyen AU - Seenae Eum AU - Cyrille K. Cornelio AU - Arthur F. Harralson TI - Genome Wide Epistasis Study of On-Statin Cardiovascular Events with Iterative Feature Reduction and Selection AID - 10.1101/2020.03.31.20044255 DP - 2020 Jan 01 TA - medRxiv PG - 2020.03.31.20044255 4099 - http://medrxiv.org/content/early/2020/04/03/2020.03.31.20044255.short 4100 - http://medrxiv.org/content/early/2020/04/03/2020.03.31.20044255.full AB - Background Predicting risk for major adverse cardiovascular events (MACE) is an evidence-based practice that incorporates lifestyle, history, and other risk factors. Statins reduce risk for MACE by decreasing lipids, but it is difficult to stratify risk following initiation of a statin. Genetic risk determinants for on-statin MACE are low-effect size and impossible to generalize. Our objective was to determine high-level epistatic risk factors for on-statin MACE with GWAS-scale data.Methods Controlled-access data for 5,980 subjects taking a statin collected from Vanderbilt University Medical Center’s BioVU were obtained from dbGaP. We used Random Forest Iterative Feature Reduction and Selection (RF-IFRS) to select highly informative genetic and environmental features from a GWAS-scale dataset of patients taking statin medications. Variant-pairs were distilled into overlapping networks and assembled into individual decision trees to provide an interpretable set of variants and associated risk.Results 1,718 cases who suffered MACE and 4,172 controls were obtained from dbGaP. Pathway analysis showed that variants in genes related to vasculogenesis (FDR=0.024), angiogenesis (FDR=0.019), and carotid artery disease (FDR=0.034) were related to risk for on-statin MACE. We identified six gene-variant networks that predicted odds of on-statin MACE. The most elevated risk was found in a small subset of patients carrying variants in COL4A2, TMEM178B, SZT2, and TBXAS1 (OR=4.53, p<0.001).Conclusions The RF-IFRS method is a viable method for interpreting complex “black-box” findings from machine-learning. In this study, it identified epistatic networks that could be applied to risk estimation for on-statin MACE. Further study will seek to replicate these findings in other populations.Competing Interest StatementThe authors have declared no competing interest.Funding StatementVanderbilt University Medical Center’s BioVU is supported by institutional funding and by the Vanderbilt CTSA grant UL1 TR000445 from NCATS/NIH. This study was supported by an NIH Pharmacogenomics Research Network (PGRN) – RIKEN Center for Integrative Medical Sciences (IMS) Global Alliance, and genome-wide genotyping was funded and performed by the IMS. This study was also supported by NHLBI/NIH grants U19 HL065962 and U01 HL069757. The authors of this study are also supported by a grant from the Andrew W. Mellon Foundation (SMA) and U5 4MD010723 (AH).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesControlled access data from dbGaP cannot be shared. Summary data, intermediate outputs, and methods are available in GitHub. https://github.com/sadams-lab/manuscript_onstatin-mace-GWES